1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

18 Mar 2024
Admin
News Article

Sibylla Partners with Ono Pharma for Developing CNS Disorder Therapeutics

Sibylla inks drug discovery collaboration with Ono Pharma to develop candidates for multiple therapeutics in CNS disorders

Sibylla Biotech announced a drug discovery collaboration with Osaka-headquartered Ono Pharmaceutical Co., for accessing Sibylla’s cutting-edge Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology to identify and develop candidates for multiple therapeutic targets in the field of central nervous system (CNS) disorders.

Terms of Agreement

Under the terms of the collaboration, Sibylla is entitled to a total deal value in the three-digit millions of US dollars, including upfront payment, research, development and sales milestones, and royalties on sales. Further financial details on the collaboration have not been disclosed.

Sibylla Biotech’s Technology

Sibylla Biotech utilizes its PPI-FIT technology to design Folding Interfering Degraders (FIDs).
FIDs are small molecules that induce the degradation of a target protein by interfering with its folding pathway. The technology targets specific proteins, particularly those considered “undruggable” due to the absence of suitable pockets in their native state.
Ono Pharmaceutical plans to harness this technology to address some of the most challenging aspects of CNS drug development by targeting proteins involved in complex neurological pathways.

Words from Ono Pharma

“Sibylla's PPI-FIT technology platform has the potential to surpass the limitations of conventional methods and uncover novel CNS therapeutic targets,” said Toichi Takino, senior executive officer/executive director, discovery & research of Ono Pharmaceutical. “This collaboration is a key part of our strategy to increase efficiency in developing our pipeline in CNS areas and bring innovative solutions to patients facing serious neurological disorders.”

Words from CEO: Sibylla Biotech

“Our partnership with Ono Pharmaceutical represents a fusion of Sibylla's cutting-edge technology in protein folding simulation with Ono's extensive experience in CNS research. Together, we aim to unlock new therapeutic possibilities for patients worldwide,” commented Lidia Pieri, PhD, co-founder and chief executive officer of Sibylla Biotech. “I am honored to collaborate with the Ono Pharmaceutical team, whose rich history, expertise and culture I greatly appreciate, and all of us at Sibylla look forward to working closely with them.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!